Nav: Home

Statins and colorectal cancer

April 26, 2016

Confounding rather than causation may explain association between statin use and lower risk of colorectal cancer

Both statin use and increased cholesterol have been linked to lower risk of colorectal cancer. Some have questioned whether the apparent beneficial effects of statins are due to indication bias, which occurs when the indication (high cholesterol) for the medication under study (statin) is also related to the outcome of interest (colon cancer). A large case-control study published in this week's PLOS Medicine conducted by Ronac Mamtani, MD, MSCE, an assistant professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA, and colleagues provides evidence that indication bias may explain the link between statin use and reduced colorectal cancer risk.

The researchers identified 22,163 patients with colorectal cancer and 86,538 patients without known colorectal cancer from a computerized database of electronic records of >10 million UK patients in primary care practices (The Health Improvement Network [THIN]). They confirmed findings from previous studies that showed a decreased risk of colorectal cancer in statin users compared to non-users (OR, 0.95; 95% CI, 0.91-0.99), however, they found that the difference in the risk of colorectal cancer was not significantly different between those patients who continued statin therapy and those who discontinued (OR, 0.98; 95% CI, 0.79-1.22), suggesting that indication bias may explain the findings. Consistent with this observation, increased serum cholesterol was independently associated with decreased risk of colorectal cancer (OR, 0.89 per 1 mmol/L (~38.6 mg/dl) increase; 95% CI, 0.87-0.91).

Additionally, they observed that decreases in total serum cholesterol by >1 mmol/L at least a year before the cancer diagnosis were associated with 1.25-fold and 2.36-fold increased risk of colorectal cancer in users and nonusers of statins.

Although the researchers adjusted for numerous confounding factors in their analysis, given the observational nature of the study, the findings are limited by the potential for residual confounding by unmeasured factors.

The authors say: "Together, these data demonstrate a complex association between statins, cholesterol, and colorectal cancer, suggesting that unexplained cholesterol lowering in statin users or nonusers may be a marker of undiagnosed colorectal cancer."

They continue, "Clinical judgment should be used when considering causes of cholesterol reduction in patients, including those on statin therapy."
Research Article


This research was supported by the National Institutes of Health (grant number K23-CA187185 to RM, K08-DK095951-02 to FIS, K08-DK098272 to DSG, and K24-DK078228 to JDL). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Competing Interests:

I have read the journal's policy and the authors of this manuscript have the following competing interests: RM reports personal fees from Takeda, outside the submitted work; JDL reports personal fees from Pfizer, Merck, and AstraZeneca, and grants from Shire, Takeda, Bayer, and Nestle Health Science, outside the submitted work; FIS has received research support from Takeda, outside the submitted work; and TA reports personal fees from Roche, outside the submitted work. Pfizer, Merck, AstraZeneca, Takeda, and Bayer are manufacturers of statins. The remaining authors (DSG YXY BB JD) have declared that no competing interests exist.


Mamtani R, Lewis JD, Scott FI, Ahmad T, Goldberg DS, Datta J, et al. (2016) Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. PLoS Med 13(4): e1002007. doi:10.1371/journal.pmed.1002007

Author Affiliations:

Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America Tel-Aviv University, Tel-Aviv, Israel



Ronac Mamtani
Perelman School of Medicine at the University of Pennsylvania
Division of Hematology-Oncology
Abramson Cancer Center
Philadelphia, Pennsylvania 19104


Related Colorectal Cancer Articles:

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.
Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.
A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.
Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.
Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.
Aspirin before at-home colorectal cancer screening test didn't significantly improve ability to detect cancer precursors
Some observational studies have suggested that taking aspirin before undergoing colorectal cancer screening with a fecal immunochemical test for blood in stool might improve the ability of the test to detect cancer precursors.
Gene involved in colorectal cancer also causes breast cancer
Rare mutations in the NTHL1 gene, previously associated with colorectal cancer, also cause breast cancer and other types of cancer.
Bug that causes stomach cancer could play a role in colorectal cancer
A bacterium known for causing stomach cancer might also increase the risk of certain colorectal cancers, particularly among African Americans, according to a study led by Duke Cancer Institute researchers.
'Chromosomal catastrophes' in colorectal cancer
'Chromosomal catastrophes' have been found to occur along the evolutionary timeline of colorectal cancer development, according to new research led by Queen Mary University of London.
Colorectal cancer: Tipping the scales
Tumors of the colon are among the most prevalent cancers.
More Colorectal Cancer News and Colorectal Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at